Highlights Ivermectin, an FDA-approved anti-parasitic agent, was found to be an inhibitor of SARS-CoV-2 replication in the laboratory. Ivermectin may be effective for the treatment of early-onset mild Covid-19 in adult patients. Early viral clearance of SARS-CoV-2 was observed in treated patients. Remission of fever, cough and sore throat did not differ between those treated with or without ivermectin. No severe adverse event observed with the longer duration of ivermectin use. Larger trials will be needed to confirm these preliminary findings.
Objective We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection. Methods This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR. Results Among 556 screened patients, 400 were enrolled and 363 completed follow-up. The mean patient age was 40 years, and 59% were men. The median recovery time was 7 (4–10, treatment group) and 9 (5–12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60–0.90). The number of patients with a ≤7-day recovery was 61% (treatment group) and 44% (placebo groups) (hazard ratio, 0.06; 95% confidence interval, 0.04–0.09). The proportion of patients who remained RT-PCR positive on day 14 and whose disease did not progress was significantly lower in the treatment group than in the placebo group. Conclusions Patients with mild-to-moderate COVID-19 infection treated with ivermectin plus doxycycline recovered earlier, were less likely to progress to more serious disease, and were more likely to be COVID-19 negative by RT-PCR on day 14. Trial Registration ClinicalTrials.gov Identifier: NCT04523831. Data Repository ID Dryad. doi:10.5061/dryad.qjq2bvqf6
Introduction: Since the first detection of corona virus disease (COVID-19) cases in Dhaka, Bangladesh on 8 March, 2020, numbers are rising alarmingly. Clinical data on COVID-19 in Bangladesh is lacking. We report early findings on demographic profile, clinical presentations and short-term clinical outcomes of confirmed COVID-19 patients admitted in a large teaching hospital in Dhaka, Bangladesh with preliminary analyses of their association with mortality. Materials and Methods: In this retrospective cross-sectional study, we included reverse transcription polymerase chain reaction (RT-PCR) confirmed COVID-19 patients aged ≥ 15 years, who were admitted in Dhaka Medical College Hospital (DMCH) between May 2 and 15, 2020, the first two weeks when DMCH started admitting COVID-19 patients. Data were collected between May 25 and 29, 2020 from patients or their attendants through telephone interview by a structured questionnaire, after having appropriate consent, irrespective of outcome. One hundred and eight consecutive patients met inclusion criteria through convenient sampling from ward registrar, 102 patients could be reached over phone and data from two patients were discarded in the data cleaning process. The statistical analysis was done by the Statistical Package for the Social Sciences (SPSS) version 22.0. Results: Among the total participants (n=100), mean age was 41.7±16.3 years, 63% were male and 60% patients had positive contact history. Appearance of symptom to hospital admission time was a median of 6 days (range 1 to 21 days) and mean hospital stay was 7.77 ± 5.62 days. Predominant presenting symptoms were fever (69%), cough (54%), breathlessness (41%), fatigue (40%), anorexia (26%) and diarrhea (19%). Hypertension (21%), diabetes mellitus (16%), heart diseases including ischemic heart disease (IHD) (8%) and renal diseases including chronic kidney disease (CKD) (8%) were frequent comorbidities. Ten out of hundred patients died. Older age (p= 0.001), male sex (p= 0.007), smoking (p= 0.001), breathlessness (p=0.001) and presence of comorbidities (p= < 0.05) were significantly associated with mortality. Conclusion: Frequent positive contact history and significant association of breathlessness, smoking and comorbidities with mortality in our study reinforces that abiding by the prevention and containment process, smoking cessation, ensuring proper oxygen therapy and addressing comorbidities adequately are very important measures to mitigate COVID-19 in Bangladesh like the rest of the world. J Bangladesh Coll Phys Surg 2020; 38(0): 29-36
Asthma in Bangladesh appears to be a substantial public health problem: an estimated 7 million people including 4 million children suffer from asthma-related symptoms.
Background Globally, studies have shown conflicting results regarding the association of blood groups with SARS CoV-2 infection. Objective To observe the association between ABO blood groups and the presentation and outcomes of confirmed COVID-19 cases. Design, setting, and participants This was a prospective cohort study of patients with mild-to-moderately severe COVID-19 infections who presented in the COVID-19 unit of Dhaka Medical College Hospital and were enrolled between 01 June and 25 August, 2020. Patients were followed up for at least 30 days after disease onset. We grouped participants with A-positive and A-negative blood groups into group I and participants with other blood groups into group II. Results The cohort included 438 patients; 52 patients were lost to follow-up, five died, and 381 completed the study. The prevalence of blood group A [144 (32.9%)] was significantly higher among COVID-19 patients than in the general population (p < 0.001). The presenting age [mean (SD)] of group I [42.1 (14.5)] was higher than that of group II [38.8 (12.4), p = 0.014]. Sex (p = 0.23) and co-morbidity (hypertension, p = 0.34; diabetes, p = 0.13) did not differ between the patients in groups I and II. No differences were observed regarding important presenting symptoms, including fever (p = 0.72), cough (p = 0.69), and respiratory distress (p = 0.09). There was no significant difference in the median duration of symptoms in the two group (12 days), and conversion to the next level of severity was observed in 26 (20.6%) and 36 patients (13.8%) in group I and II, respectively. However, persistent positivity of RT-PCR at 14 days of initial positivity was more frequent among the patients in group I [24 (19%)] than among those in group II [29 (11.1%)]. Conclusions The prevalence of blood group A was higher among COVID-19 patients. Although ABO blood groups were not associated with the presentation or recovery period of COVID-19, patients with blood group A had delayed seroconversion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.